Bronchogen
Research OnlyAlso known as: AEDL, Ala-Glu-Asp-Leu, Bronchial tetrapeptide, Respiratory peptide
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
Research Statistics
Russian-only bioregulator; no independent Western replication of lung peptide effects.
Research Dossier
Overview
What is Bronchogen and what does the research say?
Mechanism of Action
The proposed mechanisms of Bronchogen are based entirely on Russian bioregulator research from the St. Petersburg Institute of Bioregulation and Gerontology. No independent Western validation exists for any claimed mechanisms.
How It Works (Simplified)
Bronchogen is claimed to target bronchial tissue through gene expression modulation:
Claimed to selectively bind bronchial tissue DNA sequences and modulate gene expression patterns relevant to respiratory function.
Proposed to stimulate bronchial mucosal regeneration and support repair of respiratory epithelium, particularly in aged tissue.
Claimed to modulate cytokine profiles and immune responses within respiratory mucosa for improved local defense.
Part of Khavinson’s bioregulator theory that short peptides can selectively target specific tissue types through sequence-specific DNA binding.
Scientific Pathways
Proposed Bronchial Targeting Pathway (Tissue-Specific)
Bronchogen (AEDL) → Cell Penetration → Nuclear Entry
↓
Bronchial-Specific DNA Binding → Gene Expression Changes
↓
Epithelial Repair & Function Genes ↑Proposed Mucosal Regeneration Pathway (Repair)
Bronchogen → Bronchial Epithelial Cells → Regeneration Gene Activation
↓
Mucosal Repair → Improved Barrier FunctionNote: These pathways are based on Russian bioregulator theory and have not been independently validated by Western research.
Important Limitations
- 100% of research from single institute (St. Petersburg Institute of Bioregulation and Gerontology)
- No independent Western replication of any claimed effects
- No controlled human clinical trials with placebo comparison
- Pharmacokinetics, bioavailability, and optimal dosing completely uncharacterized
- Mechanism of tissue-specific targeting is theoretical and unvalidated
- Claims of gene expression modulation lack rigorous molecular characterization
- Translation from Russian observational studies to therapeutic benefit is unconfirmed
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on Russian protocols: Initial effects on bronchial tissue gene expression may begin. Cell culture studies suggest peptide-DNA interactions occur within days. No validated human pharmacokinetic data.
Russian protocols typically involve treatment courses of 10-20 days. Claimed effects on bronchial mucosal regeneration may develop. Immune modulation in respiratory tract suggested.
Extended treatment in Russian studies shows claimed improvements in respiratory function markers. Tissue regeneration effects reported in animal models. Human response timelines are speculative.
Long-term effects based on Russian observational studies in elderly populations. Cyclical treatment protocols often recommended (treatment courses with rest periods). Optimal duration unknown.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Bronchogen product quality
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Bronchogen with other peptides. Based on published research and mechanistic considerations.
Epithalon
CompatibleBoth Khavinson bioregulator peptides with distinct tissue targets - epithalon for pineal/longevity, bronchogen for bronchial epithelium. No known direct interactions.
Thymalin
CompatibleThymalin targets thymic immune function while bronchogen targets respiratory epithelium. May have complementary effects for respiratory immune support.
Vilon
CompatibleBoth short Russian bioregulator peptides - vilon for immune modulation, bronchogen for bronchial tissue. Different tissue targets with no known contraindications.
Thymosin-Alpha-1
CompatibleTa1 provides broad immune modulation while bronchogen targets bronchial tissue specifically. May complement each other for respiratory health.
BPC-157
CompatibleBPC-157 provides systemic tissue healing while bronchogen targets bronchial epithelium specifically. No known contraindications in combination.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Bronchogen
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3, 225Ac-DOTA-JR11, Alpha-PRRT +1 more
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
BT5528
Bicycle Toxin Conjugate 5528, EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. Phase 1/2 dose expansion ongoing with 67% ORR reported in EphA2-positive urothelial cancer patients.
Cardiogen
AED, Ala-Glu-Asp, Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp) developed by Russian scientist Vladimir Khavinson for cardiac tissue support. Claimed to target cardiomyocyte gene expression and provide cardioprotective effects. No Western clinical validation exists; evidence limited to Russian preclinical and observational studies.
Chonluten
EDG-GI, Glu-Asp-Gly (GI), GI tract tripeptide +1 more
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01, Evaxion EVX-01, AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1 data in melanoma showed 67% overall response rate when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.
Livagen
KED, Lys-Glu-Asp, Hepatogen
A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support liver function and modulate hepatic gene expression. Minimal Western validation exists; all research originates from Russian institutions with no controlled human clinical trials.